Skip to main content
PMC home page
Springer logoLink to Springer
. 2020 Nov 2;87(4):585–586. doi: 10.1007/s00280-020-04185-y

Correction to: A placebo‑controlled, double‑blind, randomized study of recombinant thrombomodulin (ART‑123) to prevent oxaliplatin‑induced peripheral neuropathy

Masahito Kotaka 1,✉, Yoji Saito 2, Takeshi Kato 3,4, Hironaga Satake 5,6, Akitaka Makiyama 7,8, Yasushi Tsuji 9, Katsunori Shinozaki 10, Toshiyoshi Fujiwara 11, Tsunekazu Mizushima 12, Yasushi Harihara 13, Naoki Nagata 14, Naoto Kurihara 15, Masahiko Ando 16, Genichi Kusakawa 17, Takumi Sakai 17, Yugo Uchida 17, Mikihiro Takamoto 17, Saki Kimoto 17, Ichinosuke Hyodo 18,19
PMCID: PMC8182840  PMID: 33136172

Correction to: Cancer Chemotherapy and Pharmacology (2020) 86:607–618 10.1007/s00280-020-04135-8

In the Original publication of the article, the authors found an error in the “Results” section under the heading “Abstract”. The corrected text is given below:

Seventy-nine participants (placebo n = 28, 1-day ART n = 27, 3-day ART n = 24) received study drugs. The least-squares mean FACT/GOG-Ntx-12 scores at cycle 12 from the mixed effect model for repeated measures were 28.9 with placebo, 36.3 with 1-day ART [vs. placebo: 7.3 (95% CI 1.9 to 12.8, p = 0.009)], and 32.3 with 3-day ART [vs. placebo: 3.4 (95% CI −2.1 to 9.0, p = 0.222)].

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Articles from Cancer Chemotherapy and Pharmacology are provided here courtesy of Springer

RESOURCES